Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005)

Journal of Biochemistry and Molecular Biology

Volumn 40, Issue 6, 2007, Pages 881-887

  Do, Kyung Lee ^a   Kim, Yuna ^a   Kun, Sup Park ^a   Jae, Wook Yang ^b   Kim, Kyungjae ^a   Nam, Joo Ha ^a  

^a Sahmyook University   (South Korea)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Daptomycin; Linezolid; Tigecycline and vancomycin resistant enterococci

Indexed keywords

ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DRUG DERIVATIVE; LINEZOLID; MINOCYCLINE; OXAZOLIDINONE DERIVATIVE; PSEUDOMONIC ACID; QUINUPRISTIN-DALFOPRISTIN; TIGECYCLINE; UNCLASSIFIED DRUG; VIRGINIAMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; COMPARATIVE STUDY; DRUG EFFECT; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; HUMAN; ISOLATION AND PURIFICATION; KOREA; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; KOREA; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; MUPIROCIN; OXAZOLIDINONES; VANCOMYCIN RESISTANCE; VIRGINIAMYCIN;

BACTERIA (MICROORGANISMS); ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM;

EID: 36949010591     PISSN: 12258687     EISSN: 02191024     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Acarturk, E., Attila, G., Bozkurt, A., Akplnar, O., Matyar, S. and Seydaoglu, G. (2005) Insertion/deletion polymorphism of the angiotensin converting enzyme in coronary artery disease in Southern Turkey. J. Biochem. Mol. Biol. 38, 486-490.
2. Akins, R. L. and Rybak, M. J. (2001) Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus isolates in and in vitro pharmacodynamic model with simulated endocardial vegetation. Antimicrob. Agents Chemother. 45, 454-459.
3. Betriu, C., Gomez, M., Rodriguez-Avial, I., Culebras, E. and Picazo, J. J. (2005) In vitro activity of tigecycline against ampicillin-resistant Haemophilus influenzae isolates. J. Antimicrob. Chemother. 55, 809-810.
4. Bouchillon, S. K., Hoban, D. J., Johnson, B. M., Stevens, T. M., Dowzicky, M. J., Wu, D. H. and Bradford, P. A. (2005) In vitro evaluation of tigecycline and comparative agents in 3,049 clinical isolates: 2001 to 2002. Diagn. Microbiol. Infect. Dis. 51, 291-295.
5. Centers for Disease Control and Prevention (1993) Nosocomial enterococci resistant to vancomycin-United States, 1989-1993. Morbid. Mortal. Weekly Rep. 42, 597-599.
6. Choi, S. S., Kim, B. S. and Ha, N. J. (2002) Isolation, identification and characterization of vancomycin-resistant enterococci from raw milk. J. Microbiol. 40, 170-172.
7. Choi, J. H., Zhang, P. C., Park, K. W., Cho, Y. S. and Oh, B. H. (2005) The association between the T102C polymorphism of the HTR2A serotonin receptor gene and HDL cholesterol level in Koreans. J. Biochem. Mol. Biol. 38, 238-242.
8. Diekema, D. J. and Jones, R. N. (2001) Oxazolidinone antibiotics. Lancet 358, 1975-1982.
9. Emori, T. G. and Gaynes, R. P. (1993) An overview of nosocomial infections, including the role of microbiology laboratory. Clin. Microb. Drug Resist. 6, 313-318.
10. Fritsche, T. R., Sader, H. S., Stilwell, M. G., Dowzicky, M. J and Jones, R. N. (2005a) Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn. Microbiol. Infect. Dis. 52, 187-193.
11. Fritsche, T. R., Sader, H. S., Stilwell, M. G., Dowzicky, M. J. and Jones, R. N. (2005b) Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagn. Microbiol. Infect. Dis. 52, 195-201.
12. Fuchs, P. C., Barry, A. L. and Brown, S. D. (2000) Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn. Microbiol. Infect. Dis. 38, 51-58.
13. Hsueh, P. R., Chen, W. H., Teng, L. J and Luh, K. T. (2005) Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int. J. Antimicrob. Agents 26, 43-49.
14. Jones, R. N. (2003) Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the Sentry Antimicrobial Surveillance Program (1997-2001). Semin. Respir. Crit. Care Med. 24, 121-133.
15. Kim, J. M. and Song, Y. G. (1998) Vancomycin-resistant enterococcal infections in Korea. Yonsei Med. J. 39, 562-568.
16. Kim, S. M., Shim, E. S. and Seong, C. N. (2001) Prevalence and antibiotic susceptibility of vancomycin-resistant enterococci in chicken intestines and fecal samples from healthy young children and intensive care unit patients. J. Microbiol. 39, 116-120.
17. Klare, I., Heier, H., Claus, H., Reissbrodt, R. and Witte, W. (1995) VanA-mediated high-level glycopeptide resistance in Enterococcus faecium from animal husbandry. Fems Microbiol. Lett. 125, 165-172.
18. LaPlante, K. L. and Rybak, M. J. (2004) Clinical glycopeptide- intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. Diagn. Microbiol. Infect. Dis. 50, 125-130.
19. Meka, V. G. and Gold, H. S. (2004) Antimicrobial resistance to linezolid. Clin. Infect. Dis. 39, 1010-1015.
20. Moellering, R. C. (1992) Emergence of Enterococcus as a significant pathogen. Clin. Infect. Dis. 14, 1173-1178.
21. Nathwani, D. (2005) Tigecycline: clinical evidence and formulary positioning. Int. J. Antimicrob. Agents 25, 185-192.
22. National Committee for Clinical Laboratory Standards (NCCLS) (2003) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. Wayne PA: NCCLS.
23. th information supplement M100-S15. Wayne PA: NCCLS.
24. Package insert (2003) Cubicin (daptomycin for infection). Lexington MA. (Cubist Phamaceuticals, Inc.) Available at http://www.cubist.com/shared/ cubicin_label.pdf. Accessed on September 22, 2003.
25. Patel, R. (2003) Clinical impact of vancomycin-resistant enterococci. J. Antimicrob. Chemother. 51 (Suppl.), 13-21.
26. Raad, I., Hachem, R. and Hanna, H. (2001) Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline. Antimicrob. Agents Chemother. 45, 3202-3204.
27. Raad, I., Hachem, R., Hanna, H., Afif, C., Escalante, C., Kantarjian, H. and Rolston, K. (2004) Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections J. Antimicrob. Chemother. 53, 646-649.
28. Ross, J. E., Anderegg, T. R., Sader, H. S., Fritsche, T. R. and Jones, R. N. (2004) Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. Diagn. Microbiol. Infect. Dis. 52, 53-58.
29. Sader, S. H., Fritsche, T. R. and Jones, R. N. (2005) Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003). Diagn. Microbiol. Infect. Dis. 53, 329-332.
30. Sader, H. S., Jones, R. N., Dowzicky, M. J. and Fritsche, T. R. (2005) Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn. Microbiol. Infect. Dis. 52, 203-208.
31. Sader, H. S., Streit, J. M., Fritsche, T. R. and Jones, R. N. (2004) Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide. Diagn. Microbiol. Infect. Dis. 50, 201-204.
32. Sakouloas, G., Eliopoulos, G. M., Alder, J. and Thauvin-Eliopoulos, C. (2003) Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 1714-1718.
33. Smith, P. F., Booker, B. M., Ogundele, A. B. and Kelchin, P. (2005) Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center. Diagn. Microbiol. Infect. Dis. 52, 255-259.
34. Steenbergen, J. N., Alder, J., Thorne, G. M. and Talley, F. P. (2005) Dpatomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J. Antimicrob. Chemother. 55, 283-288.
35. Streit, J. M., Jones, R. N. and Sader, H. S. (2004) Daptomycin activity and spectrum: A worldwide sample of 6,737 Gram-positive organisms. J. Antimicrob. Chemother. 53, 669-674.
36. Wenzel, R. P. (2004) The antibiotic pipeline-challenges, costs and values. N. Engl. J. Med. 351, 523-526.
37. Wesson, K. M., Lerner, D. S., Silverberg, N. B. and Weinberg, J. M. (2004) Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology. Dis. Mon. 50, 395-406.
38. Witte, W. (1997) Impact of antibiotic use in animal feeding on resistance of bacterial pathogens in humans. Ciba. Found. Symp. 207, 61-71.
39. World Health Organization (WHO) WHO Global strategy for containment of antimicrobial resistance. WHO/CDS/CSR/DRS/2001.2.
40. Yang, J. W., Lee, D. K., Kim, Y. A., Kang, B. Y., Kim, K. J. and Ha, N. J. (2007) Occurrence of the van genes in Enterococcus faecalis and Enterococcus faecium from clinical isolates in Korea. Arch. Pharm. Res. 30, 329-336.